Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients

被引:4
|
作者
Naicker, Derisha [1 ]
Reed, Peter W. [2 ]
Ronaldson, Jane [1 ]
Kara, Tonya [1 ]
Wong, William [1 ]
Prestidge, Chanel [1 ]
机构
[1] Starship Childrens Hosp, Dept Pediat Nephrol, Pk Rd,Private Bag 92024, Auckland 1142, New Zealand
[2] Starship Childrens Hosp, Childrens Res Ctr, Auckland, New Zealand
关键词
Calcineurin inhibitor; Generic Immunosuppression; Renal; Tacrolimus; Transplantation; IMMUNOSUPPRESSION; PROGRAF; DRUGS;
D O I
10.1007/s00467-017-3707-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Bioequivalence between Tacrolimus Prograf (R) and generic tacrolimus formulations has been demonstrated in adult populations,however clinical experience and safety data regarding generic tacrolimus in pediatric transplant recipients is limited. This study aimed to evaluate conversion from Tacrolimus Prograf (R) to Sandoz (R) in pediatric renal transplant recipients nationwide. The primary outcome was a change in mean trough tacrolimus concentration. Additionally, changes in tacrolimus intra-patient coefficient of variation (CoV), allograft function, requirement for dose adjustments, and episodes of biopsy-proven rejection were evaluated. Methods Retrospective cohort study in 37 pediatric renal transplant recipients who switched to Tacrolimus Sandoz (R). Each patient had three pre-conversion tacrolimus trough and creatinine concentrations within the 4 months prior and three post-conversion concentrations on day 3, 10, and the next subsequent level. Mean pre-and post-conversion tacrolimus trough concentrations and glomerular filtration rate (eGFR) were calculated. Tacrolimus concentration, CoV, and creatinine differences were compared by paired t test. Results Thirty-seven patients (41% females, age 3-18 years) were included. Average intra-patient difference in trough tacrolimus concentration was 0.05 mu g/l (95% CI -0.37 to 0.47). Average intra-patient difference in eGFR was -1.20 ml/min/1.73(2) (95% CI -3.53 to 1.13). Three patients had acute rejection during 12 months post-conversion compared to none during 12 months pre-conversion. Conclusions Pediatric renal transplant recipients can be converted from Tacrolimus Prograf (R) to Sandoz (R) with negligible change in trough concentration, dose adjustments, or immediate allograft function. Of concern was the number of acute rejection episodes, however non-adherence contributed to at least one episode and this difference was determined clinically and statistically not significant.
引用
收藏
页码:2125 / 2131
页数:7
相关论文
共 50 条
  • [41] Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients
    Zhao, W.
    Elie, V.
    Roussey, G.
    Brochard, K.
    Niaudet, P.
    Leroy, V.
    Loirat, C.
    Cochat, P.
    Cloarec, S.
    Andre, J. L.
    Garaix, F.
    Bensman, A.
    Fakhoury, M.
    Jacqz-Aigrain, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (06) : 609 - 618
  • [42] The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients
    Madsen, Mads Juul
    Bergmann, Troels K.
    Brosen, Kim
    Thiesson, Helle Charlotte
    DRUGS IN R&D, 2017, 17 (02) : 279 - 286
  • [43] Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: A single-center experience
    Ferraresso, M
    Ghio, L
    Edefonti, A
    Garavaglia, R
    Pozzoli, E
    Berardinelli, L
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (7-8) : 3590 - 3591
  • [44] THE IMPACT OF CONVERSION FROM PROGRAF TO GENERIC TACROLIMUS IN LIVER TRANSPLANT RECIPIENTS WITH STABLE GRAFT FUNCTION
    Del Gaudio, Massimo
    Cescon, Matteo
    Ravaioli, Matteo
    Cucchetti, Alessandro
    Bertuzzo, Valentina
    Amaduzzi, Annalisa
    Morelli, Maria Cristina
    Pinna, Antonio Daniele
    TRANSPLANT INTERNATIONAL, 2017, 30 : 289 - 289
  • [45] The Impact of Conversion from Prograf to Generic Tacrolimus in Liver Transplant Recipients With Stable Graft Function
    Del Gaudio, Massimo
    Cescon, Matteo
    Bertuzzo, Valentina
    Amaduzzi, Annalisa
    Ravaioli, Matteo
    Cucchetti, Alessandro
    Pinna, Antonio Daniele
    TRANSPLANTATION, 2017, 101 (05) : S11 - S11
  • [46] Tacrolimus trough levels in kidney transplant recipients
    Hwang, Young Hui
    Kim, Hyunjung
    Min, Kyungok
    Yang, Jaeseok
    BMC NEPHROLOGY, 2021, 22 (01)
  • [47] Tacrolimus trough levels in kidney transplant recipients
    Young Hui Hwang
    Hyunjung Kim
    Kyungok Min
    Jaeseok Yang
    BMC Nephrology, 22
  • [48] Pharmacokinetics of tacrolimus in pediatric renal transplant recipients
    Shishido, S
    Asanuma, H
    Tajima, E
    Honda, M
    Nakai, H
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) : 1066 - 1068
  • [49] Dose Conversion Factor Between Cyclosporine and Tacrolimus in Pediatric Heart Transplant Recipients.
    Notaro, E.
    Brown, L.
    Albers, E.
    Law, S.
    Law, Y.
    Kemna, M.
    TRANSPLANTATION, 2014, 98 : 235 - 235
  • [50] A Pharmacokinetic Comparison of Generic Tacrolimus (Hecoria™) Versus Prograf® in Subpopulations of Kidney Transplant Recipients.
    Bloom, R. D.
    Trofe-Clark, J.
    Wiland, A.
    Sadaka, B.
    Alloway, R. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 404 - 405